EP2937348A4 - CRYSTALLINE FORM OF COMPOUND AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PROCESS FOR PREPARING THE SAME - Google Patents

CRYSTALLINE FORM OF COMPOUND AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PROCESS FOR PREPARING THE SAME

Info

Publication number: EP2937348A4
Authority: EP; European Patent Office
Prior art keywords: preparing; compound; same; crystalline form; receptor antagonist
Prior art date: 2012-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13864994.2A

Other languages

German (de)

French (fr)

Other versions

EP2937348B1 (en

EP2937348A1 (en

Inventor

Chen Jiang

Aichen Wang

Dedong Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KBP Biosciences Pte Ltd

Original Assignee

KBP Biosciences Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-22

Filing date

2013-12-23

Publication date

2016-09-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50977609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2937348(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-23 Application filed by KBP Biosciences Co Ltd filed Critical KBP Biosciences Co Ltd

2013-12-23 Priority to EP21194531.6A priority Critical patent/EP3954688A1/en

2015-10-28 Publication of EP2937348A1 publication Critical patent/EP2937348A1/en

2016-09-07 Publication of EP2937348A4 publication Critical patent/EP2937348A4/en

2021-09-08 Application granted granted Critical

2021-09-08 Publication of EP2937348B1 publication Critical patent/EP2937348B1/en

Status Active legal-status Critical Current

2033-12-23 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EP13864994.2A 2012-12-22 2013-12-23 Process for the preparation of a compound used as mineralocorticoid receptor antagonist Active EP2937348B1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP21194531.6A EP3954688A1 (en)	2012-12-22	2013-12-23	Crystal forms of compound used as mineralocorticoid receptor antagonist and methods for their preparation

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201210563636		2012-12-22
PCT/CN2013/090252 WO2014094664A1 (en)	2012-12-22	2013-12-23	Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21194531.6A Division EP3954688A1 (en)	2012-12-22	2013-12-23	Crystal forms of compound used as mineralocorticoid receptor antagonist and methods for their preparation

Publications (3)

Publication Number	Publication Date
EP2937348A1 EP2937348A1 (en)	2015-10-28
EP2937348A4 true EP2937348A4 (en)	2016-09-07
EP2937348B1 EP2937348B1 (en)	2021-09-08

Family

ID=50977609

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP21194531.6A Withdrawn EP3954688A1 (en)	2012-12-22	2013-12-23	Crystal forms of compound used as mineralocorticoid receptor antagonist and methods for their preparation
EP13864994.2A Active EP2937348B1 (en)	2012-12-22	2013-12-23	Process for the preparation of a compound used as mineralocorticoid receptor antagonist

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP21194531.6A Withdrawn EP3954688A1 (en)	2012-12-22	2013-12-23	Crystal forms of compound used as mineralocorticoid receptor antagonist and methods for their preparation

Country Status (17)

Country	Link
US (1)	US9809589B2 (en)
EP (2)	EP3954688A1 (en)
JP (6)	JP2016503041A (en)
KR (1)	KR101737883B1 (en)
CN (1)	CN105026391B (en)
AU (1)	AU2013362400B2 (en)
BR (1)	BR112015014839B1 (en)
CA (1)	CA2895968C (en)
ES (1)	ES2897496T3 (en)
HK (2)	HK1212676A1 (en)
IL (1)	IL239581B (en)
MX (1)	MX360889B (en)
NZ (1)	NZ709361A (en)
RU (1)	RU2622105C2 (en)
SG (1)	SG11201504928XA (en)
WO (1)	WO2014094664A1 (en)
ZA (1)	ZA201504485B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ709361A (en) *	2012-12-22	2016-09-30	Kbp Biosciences Co Ltd	Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
IL265560B (en) *	2016-09-24	2022-07-01	Kbp Biosciences Co Ltd	Preparations containing a mineralocorticoid receptor antagonist and their uses
PE20212179A1 (en) *	2019-03-01	2021-11-09	Kbp Biosciences Co Ltd	PROCEDURE FOR PREPARING A FUSED TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012022121A1 (en) *	2010-08-18	2012-02-23	山东轩竹医药科技有限公司	Fused ring compound for use as mineralocorticoid receptor antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5245716B1 (en) *	1970-07-10	1977-11-17
CN85101404A (en) *	1985-05-16	1987-01-17	帝人株式会社	The production process of cephalosporins derivatives
JPH04235188A (en) *	1990-06-19	1992-08-24	Takeda Chem Ind Ltd	Crystal of penem compound, production thereof and antimicrobial agent
DE4235133A1 (en) *	1992-10-19	1994-04-21	Bayer Ag	Crystalline (R) - (-) - 2-cycloheptyl-N-methylsulfonyl- [4- (2-quinolinyl-methoxy) phenyl] acetamide
JP3623531B2 (en) *	1993-06-07	2005-02-23	ビーエーエスエフアクチェンゲゼルシャフト	Process for producing crystalline L-ascorbic acid-2-phosphate magnesium salt
CN1095284C (en) *	1996-06-28	2002-11-27	皇家菲利浦电子有限公司	Method and arrangement for transmitting teletext pages
JP2001501180A (en) *	1996-09-05	2001-01-30	アストラ・フアーマシユウテイカルズ・リミテツド	New arylpyridazine
DE60311861T2 (en)	2002-11-22	2007-11-22	Active Biotech Ab	PYRAZOLOCHINOLINE WITH IMMUNOMODULATING EFFECT
AU2006225699B2 (en) *	2005-03-21	2011-02-24	Eisai R & D Management Co., Ltd.	Crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1- methylpyridin-2(1H)-one and process for producing the same
DE102007063671A1 (en) *	2007-11-13	2009-06-25	Sanofi-Aventis Deutschland Gmbh	New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
EP2623498B1 (en) *	2010-09-30	2015-11-18	Toyama Chemical Co., Ltd.	Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
NZ709361A (en) *	2012-12-22	2016-09-30	Kbp Biosciences Co Ltd	Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor

2013
- 2013-12-23 NZ NZ709361A patent/NZ709361A/en unknown
- 2013-12-23 EP EP21194531.6A patent/EP3954688A1/en not_active Withdrawn
- 2013-12-23 CA CA2895968A patent/CA2895968C/en active Active
- 2013-12-23 BR BR112015014839-5A patent/BR112015014839B1/en active IP Right Grant
- 2013-12-23 EP EP13864994.2A patent/EP2937348B1/en active Active
- 2013-12-23 WO PCT/CN2013/090252 patent/WO2014094664A1/en active Application Filing
- 2013-12-23 KR KR1020157019924A patent/KR101737883B1/en active Active
- 2013-12-23 MX MX2015008193A patent/MX360889B/en active IP Right Grant
- 2013-12-23 SG SG11201504928XA patent/SG11201504928XA/en unknown
- 2013-12-23 JP JP2015548180A patent/JP2016503041A/en active Pending
- 2013-12-23 ES ES13864994T patent/ES2897496T3/en active Active
- 2013-12-23 US US14/653,933 patent/US9809589B2/en active Active
- 2013-12-23 CN CN201380066871.7A patent/CN105026391B/en active Active
- 2013-12-23 AU AU2013362400A patent/AU2013362400B2/en active Active
- 2013-12-23 RU RU2015130222A patent/RU2622105C2/en active
2015
- 2015-06-22 ZA ZA2015/04485A patent/ZA201504485B/en unknown
- 2015-06-22 IL IL239581A patent/IL239581B/en active IP Right Grant
2016
- 2016-01-15 HK HK16100440.8A patent/HK1212676A1/en unknown
- 2016-05-03 HK HK16105012.5A patent/HK1217019A1/en unknown
2017
- 2017-07-04 JP JP2017131078A patent/JP2017165787A/en active Pending
2019
- 2019-02-05 JP JP2019018876A patent/JP2019065057A/en active Pending
2020
- 2020-04-16 JP JP2020073415A patent/JP6986197B6/en active Active
2021
- 2021-11-02 JP JP2021179425A patent/JP2022009922A/en not_active Withdrawn
2023
- 2023-11-17 JP JP2023195879A patent/JP2024009114A/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012022121A1 (en) *	2010-08-18	2012-02-23	山东轩竹医药科技有限公司	Fused ring compound for use as mineralocorticoid receptor antagonist
EP2607363A1 (en) *	2010-08-18	2013-06-26	KBP Biosciences Co., Ltd.	Fused ring compound for use as mineralocorticoid receptor antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BYRN, S. ET AL.: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1995, pages 945 - 954, XP000996386, ISSN: 0724-8741, DOI: 10.1023/A:1016241927429 *

Also Published As

Publication number	Publication date
MX360889B (en)	2018-11-20
US9809589B2 (en)	2017-11-07
JP2020109132A (en)	2020-07-16
JP6986197B2 (en)	2021-12-22
US20150336950A1 (en)	2015-11-26
CA2895968A1 (en)	2014-06-26
JP2016503041A (en)	2016-02-01
IL239581B (en)	2019-09-26
HK1212676A1 (en)	2016-06-17
AU2013362400A1 (en)	2015-07-09
NZ709361A (en)	2016-09-30
JP6986197B6 (en)	2022-01-19
JP2019065057A (en)	2019-04-25
BR112015014839B1 (en)	2022-09-06
IL239581A0 (en)	2015-08-31
JP2024009114A (en)	2024-01-19
KR101737883B1 (en)	2017-05-19
ZA201504485B (en)	2016-05-25
ES2897496T3 (en)	2022-03-01
EP2937348B1 (en)	2021-09-08
AU2013362400B2 (en)	2016-07-28
RU2622105C2 (en)	2017-06-13
MX2015008193A (en)	2016-02-05
WO2014094664A1 (en)	2014-06-26
EP3954688A1 (en)	2022-02-16
KR20150103080A (en)	2015-09-09
EP2937348A1 (en)	2015-10-28
CN105026391A (en)	2015-11-04
HK1217019A1 (en)	2016-12-16
CN105026391B (en)	2016-11-16
BR112015014839A2 (en)	2017-07-11
RU2015130222A (en)	2017-01-27
JP2017165787A (en)	2017-09-21
JP2022009922A (en)	2022-01-14
SG11201504928XA (en)	2015-07-30
CA2895968C (en)	2018-10-30

Publication	Publication Date	Title
EP2780307A4 (en)	2015-06-17	PROCESS FOR THE PREPARATION OF HYDROFLUOROOLEFINS
EP2680697A4 (en)	2014-08-20	PROCESS FOR THE PREPARATION OF ANTAGONIST OF OREXIN RECEPTORS
EP2573070A4 (en)	2013-10-09	CRYSTALLINE FORM OF (S) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PROCESS FOR PREPARING SAME AND USE THEREOF
EP2940024A4 (en)	2016-06-15	BENZOXAZINE COMPOUND AND OXAZOLIDINONE, PREPARATION METHOD AND APPLICATION THEREOF
EP2856541A4 (en)	2016-01-27	PROCESS FOR THE PREPARATION OF CRYSTALLINE ELECTRODE SUBSTANCES AND SUBSTANCES OBTAINED THEREBY
EP2797975A4 (en)	2015-12-02	PROCESS FOR THE PREPARATION OF MICROCELLULAR POLYURETHANE ELASTOMERS
EP2666797A4 (en)	2015-09-02	OLEFIN BLOCK COPOLYMER AND PROCESS FOR PREPARING THE SAME
EP3470400A4 (en)	2019-04-17	CRYSTALLINE FORM OF OZANIMOD, CRYSTALLINE FORM OF ITS HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME
IL229037A0 (en)	2013-12-31	Process for the preparation of deuterated compounds containing n - alkyl groups
EP2676965A4 (en)	2014-07-30	ARYL GLYCOSIDE COMPOUND, ITS PREPARATION AND USE METHOD
EP2912211A4 (en)	2016-11-23	COATING COMPOSITION, COMPOSITE PREPARED USING THE COATING COMPOSITION AND PROCESS FOR PREPARING THE SAME
EP2632889A4 (en)	2015-01-07	INTERMEDIATE COMPOUNDS AND PROCESS FOR PREPARING FINGOLIMOD
EP2573072A4 (en)	2013-11-13	INDENOQUINOLONE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
EP2619169A4 (en)	2016-01-06	PROCESS FOR THE PREPARATION OF BROMOURÉE
EP2937326A4 (en)	2016-07-27	PROCESS FOR THE PREPARATION OF 1, 3, 3, 3-TETRAFLUOROPROPENE
EP2650049A4 (en)	2014-05-21	HYDROTREATING CATALYST AND PROCESS FOR PREPARING THE SAME
EP2940196A4 (en)	2016-01-20	PROCESS FOR THE PRODUCTION OF SiC MONOCRYSTAL OF TYPE n
EP2759529A4 (en)	2015-05-20	PROCESS FOR PREPARING 1-PALMITOYL-3-ACETYLGLYCEROL AND PROCESS FOR PREPARING 1-PALMITOYL-2-LINOLEYL-3-ACETYLGLYCEROL USING THE SAME
EP2514720A4 (en)	2013-08-21	PROCESS FOR THE PREPARATION OF HIGH DENSITY ZINC OXIDE GRANULES OF NANOSCALE DIMENSION
EP2543662A4 (en)	2013-08-21	PROCESS FOR THE PREPARATION OF A SOLUTION OF AN ALKYL METHANESULFONATE
EP2831036A4 (en)	2015-11-18	PROCESS FOR THE PREPARATION OF ALKYL ESTERS OF FLUOROLEUCIN
EP2805952A4 (en)	2015-07-01	CRYSTALLINE FORM OF SALT (6S) -5-METHYLTETRAHYDROFOLATE AND PROCESS FOR PREPARATION THEREOF
EP2937348A4 (en)	2016-09-07	CRYSTALLINE FORM OF COMPOUND AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PROCESS FOR PREPARING THE SAME
EP2778168A4 (en)	2015-08-05	PYRROLOPYRROLEDIONE-THIOPHENEQUINONE COMPOUND, PROCESS FOR PREPARING THE SAME AND USE THEREOF
EP2660271A4 (en)	2014-07-09	POLYCARBONATE-POLYSILOXANE COPOLYMER AND PROCESS FOR PREPARING THE SAME

Legal Events

Date	Code	Title	Description
2015-09-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-10-28	17P	Request for examination filed	Effective date: 20150722
2015-10-28	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-10-28	AX	Request for extension of the european patent	Extension state: BA ME
2016-03-30	DAX	Request for extension of the european patent (deleted)
2016-06-17	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1212676 Country of ref document: HK
2016-09-07	A4	Supplementary search report drawn up and despatched	Effective date: 20160809
2016-09-07	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 29/00 20060101ALI20160803BHEP Ipc: A61P 5/40 20060101ALI20160803BHEP Ipc: A61P 9/06 20060101ALI20160803BHEP Ipc: A61P 7/00 20060101ALI20160803BHEP Ipc: A61K 31/4745 20060101ALI20160803BHEP Ipc: A61P 13/12 20060101ALI20160803BHEP Ipc: A61P 25/00 20060101ALI20160803BHEP Ipc: A61P 9/00 20060101ALI20160803BHEP Ipc: A61P 9/12 20060101ALI20160803BHEP Ipc: C07D 471/04 20060101AFI20160803BHEP Ipc: A61P 9/04 20060101ALI20160803BHEP Ipc: A61P 9/10 20060101ALI20160803BHEP
2019-02-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-03-13	17Q	First examination report despatched	Effective date: 20190211
2020-09-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-05-16	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-05-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-06-09	INTG	Intention to grant announced	Effective date: 20210517
2021-06-09	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: KBP BIOSCIENCES PTE. LTD.
2021-07-30	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2021-08-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2021-08-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2021-09-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-09-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2021-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1428507 Country of ref document: AT Kind code of ref document: T Effective date: 20210915
2021-09-23	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602013079212 Country of ref document: DE
2021-09-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2021-12-27	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2022-01-12	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20210908
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211208 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211208 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2022-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1428507 Country of ref document: AT Kind code of ref document: T Effective date: 20210908
2022-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211209
2022-03-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2897496 Country of ref document: ES Kind code of ref document: T3 Effective date: 20220301
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220108 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220110 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2022-06-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602013079212 Country of ref document: DE
2022-07-15	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2022-07-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2022-07-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2022-08-17	26N	No opposition filed	Effective date: 20220609
2022-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2022-09-26	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20211231
2022-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211223 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211223
2022-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231
2022-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131223
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2023-07-05	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230526
2024-04-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240111 Year of fee payment: 11
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2024-06-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602013079212 Country of ref document: DE Owner name: NOVO NORDISK A/S, DK Free format text: FORMER OWNER: KBP BIOSCIENCES PTE. LTD., SINGAPUR, SG
2024-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2024-09-11	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20240815 AND 20240821
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210908
2024-10-10	REG	Reference to a national code	Ref country code: ES Ref legal event code: PC2A Owner name: NOVO NORDISK A/S Effective date: 20241004
2025-01-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20241121 Year of fee payment: 12
2025-01-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20241122 Year of fee payment: 12
2025-01-20	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20241121 Year of fee payment: 12
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20241121 Year of fee payment: 12